New drug cocktail shows promise for kids with rare cancers
NCT ID NCT05468359
First seen Feb 19, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with solid tumors that have come back or not responded to treatment. The goal is to find safe doses and see if the drugs shrink tumors. The trial includes two parts: first to establish safety, then to measure response in specific rare cancers like fibrolamellar carcinoma.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Methodist Le Bonheur Healthcare
WITHDRAWNGermantown, Tennessee, 38138, United States
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.